Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug PharmaphorumTakeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.HematologyRead full story pharminent August 31, 2026 (Last updated: September 1, 2026) Pharmaphorum Takeda and Protagonist’s hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera. Hematology Read full story Post navigation Previous: ESC 2026: Evolocumab explores new frontiers in CV disease preventionNext: Lilly adds to immune drug pipeline with $2.9B Merida buyout Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026